Arch Intern Med 165:1762–1768PubMedCrossRef 12. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl BTSA1 in vivo J Med 357:905–916PubMedCrossRef 13. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide

in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970PubMedCrossRef 14. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie L-G, Gallagher JC, Pavo I, Wang J, Eriksen EF (2005) Early changes in biochemical markers of bone formation correlate with Napabucasin price improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970–3977PubMedCrossRef 15. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein MG-132 cost ML, Bilezkian JP, Rosen CJ, for the PaTH Study Investigators (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215PubMedCrossRef 16. Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751PubMedCrossRef 17. Finkelstein JS, Leder BZ, Burnett SA, Wyland JJ, Lee H, de la Paz V, Gibson K, Neer RM (2006) Effects of teriparatide, alendronate, or both on bone turnover

in osteoporotic men. J Clin Endocrinol Metab 91:2882–2887PubMedCrossRef 18. Cosman F, Nieves J, Zion M, many Woelfert L, Luckey M, Lindsay R (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566–575PubMedCrossRef 19. Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping

and continuing the antiresorptive agent. J Clin Endocrinol Metab 94:3772–3780PubMedCrossRef 20. Seibel MJ (2005) Biochemical markers of bone turnover. Part 1: biochemistry and variability. Clin Biochem Rev 26:97–122PubMed 21. Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T, EUROFORS Investigators (2008) Effects of two years of daily teriparatide treatment on bone mineral density in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591–1600PubMedCrossRef 22. Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Melo-Gomes J, Obermayer-Pietsch BM, Avramidis A, Sigurdsson G, Glüer C-C (2009) Sequential treatment of severe postmenopausal osteoporosis following teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24:726–736PubMedCrossRef 23.